PIL prays for CID probe into antibiotic drug scam in Mumbai

Image
Press Trust of India Mumbai
Last Updated : Sep 21 2014 | 12:20 PM IST
A PIL in the Bombay High Court has prayed for a CID probe into an alleged antibiotic drug scam that endangered the lives of patients last month in civic hospitals here.
On August 18, patients suffered adverse drug reactions after two antibiotics were administered intravenously by doctors at a civic-run hospital, the PIL filed by activist Ketan Tirodkar submitted.
Of the 45 patients, 28 patients suffered severe reactions. Among them one Saira Shaikh died within 24 hours of the reaction and Food and Drug Administration (FDA) officials seized Saira's records from a hospital, the PIL, which is expected to come up for hearing tomorrow, said.
A fortnight ago, 18 children at a civic-run hospital in Bhiwandi had a similar experience. Similarly, on August 22, at Brihanmumbai Municipal Corporation's (BMC) hospital in Ghatkopar, patients complained of chills and abdominal pain after being injected with two antibiotics.
FDA officials visited the hospital and seized seven samples, the PIL alleged.
The PIL said that the Municipal Corporation of Greater Mumbai (MCGM) has formed a panel to investigate the reason behind the 28 patients being taken ill.
The inquiry panel would probe whether the drugs were stored improperly or in unsuitable storage condition, or whether syringes used were contaminated. The probe would also look into the quality of drugs and injection water as well as the method of administration of injections.
As exposed by the Lentin Commission Report way back in 1986, the drug cartel in the pharmaceutical sector has been running a parallel administration in nexus with FDA officials and politicians, the petition said.
The PIL prayed that a CID probe be ordered and a case of negligence registered against FDA officials, municipal hospitals and pharmaceutical companies.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Sep 21 2014 | 12:20 PM IST

Next Story